Compare Charles River Laboratories Intl. Inc (CRL) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Yum China Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.76 (market cap $11.14B), while Yum China Holdings Inc trades at $43.85 (market cap $14.89B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.68% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | YUMC | |
|---|---|---|
Market Cap | $11.14B | $14.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $57.95 |
52-Week Low | $145.57 | $40.18 |
Enterprise Value | $14.00B | $15.78B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
YUMC trades at $43.9, up 2.05% today, with strong analyst consensus (14 Buy, 5 Hold, 0 Sell). The stock shows bullish technical signals from moving averages, though RSI levels indicate potential overbought conditions. Recent earnings beats and a P/E of 16.82 suggest reasonable valuation. Key developments include the acquisition of Pizza Hut in mainland China and a $1.5 billion capital return plan for 2026, enhancing shareholder value.
The outlook remains positive given consistent revenue growth, expanding profitability, and strategic acquisitions. Risks include execution challenges in integrating Pizza Hut and macroeconomic pressures in China. With robust cash flows and a clear growth trajectory, YUMC presents a compelling opportunity for long-term investors, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
